Medical Specialists Report Updates with CivaSheet® Directional Brachytherapy in the Treatment of Sarcoma

Section 2

Northwell Health Sends Vaccinators to Ecuador

At the request of Ecuador’s Minster of Health, and for the first time since the start of the pandemic, the Northwell Health CGH team traveled outside of the U.S. on June 13 to help get shots in arms relieve overburdened health care workers in the South American country who have been working around the clock in the race to vaccinate their population.

Fusion Marketplace Changes Healthcare Traveler Experience

Fusion Marketplace is a traveler-first driven platform giving healthcare professionals the power to make decisions in their careers that they haven't been able to in the past.

Physicians report CivaSheet®, a unidirectional LDR brachytherapy implant made by CivaTech Oncology, demonstrates up to three-year local control in recurrent retroperitoneal sarcomas when implanted during surgical resection. The crude cumulative incidence of local recurrence (LR) is 26%. To date, 21 sarcoma patients have been implanted with CivaSheet at six medical centers. Sarcoma patients tolerate the implant well with no complications following surgery. None of the 21 patients (0/21) have demonstrated local recurrence. There were no reported incidences of acute or late radiation toxicity despite the surrounding organs at risk, including small bowel, ureter and kidneys. The directional source distribution allows for safe re-irradiation or adjuvant brachytherapy boost radiation therapy in patients who have had maximum EBRT dose.

A recent publication details a patient with more than 3 years follow up. This report demonstrates “CivaSheet was associated with durable local control and significant reduction in doses to OARs including bowel, rectum, and bladder.” Additionally, “the bioabsorbability, flexibility, and easy identification on CT imaging allow this device to treat tumors in irregularly shaped cavities such as the pelvic sidewall and retroperitoneum.” The uni-directional design protects healthy tissues allowing a targeted dose with no toxicity. The novel polymer encapsulation allows unprecedented dose uniformity. “Moreover, the directional nature of this device helps increase the therapeutic ratio by avoiding unnecessary irradiation of OARs.” Furthermore, “CivaSheet expands IORT capabilities in a resource independent manner.” Application of uni-directional, planar Pd-103 LDR brachytherapy technology is safe and easy and should be considered as a standard option to escalate the dose to high-risk margins after resection.



Hyperfine Adds Medtech Leader and Visionary Scott Huennekens as Executive Chairman

Mr. Huennekens’ public boards include Chairman of Acutus Medical (IPO August 2020); Chairman of Envista (IPO September 2019); and board member of Nuvasive. He also serves as a board member and past Chairman of the Medical Device Manufacturer’s Association (MDMA).

One Drop Reports Carrie Siragusa, CPA Appointed VP of Commercial Strategy, Biosensor

Formerly Head of Innovation and Diabetes Portfolio at Sanofi, Siragusa will be part of a team bringing a multi-analyte dermal sensor (biosensor) with continuous health sensing capabilities to market with a mission to provide broader access to continuous glucose monitoring.

Barbara Moorhouse Appointed as Medica Non-Executive Director

Barbara has extensive business and management experience in the private, public, and regulated sectors.

Subscribe to Medical Device News Magazine here.

Related Articles